Kornimate/medical-research-clean huggingface dataset:
a registry for participants with cirrhosis who achieve a sustained virologic response following treatment with a sofosbuvir-based regimen without interferon for chronic hepatitis c infection

Conditions: Hepatitis C Virus Infection

Summary: the primary objective of this registry study is to assess the durability of sustained virologic response (svr) and clinical progression or regression of liver disease including the incidence of hepatocellular carcinoma following svr in participants with cirrhosis after treatment with a sofosbuvir-based regimen for hcv infection.


Eligibility criteria:
key inclusion criteria: * willing and able to provide written informed consent * have either previously participated in a gilead-sponsored hcv study and received a sofosbuvir-containing regimen without interferon or at pre-selected sites only, have received an all-oral sof-based regimen outside a clinical study. these individuals must have documentation of the regimen, start and end of treatment dates (month and year), and of having achieved svr12. * have achieved svr either in a gilead-sponsored study, as defined in the treatment protocol or for individuals who enroll after receiving an all-oral sof-based regimen outside a clinical study, svr will be defined as hcv rna \< lower limit of quantification (lloq) approximately 12 weeks following last dose of treatment. * have liver cirrhosis, as defined in the treatment protocol, and have not had a liver transplant after receiving a sof-containing regimen or individuals who enroll after receiving an all-oral sof-based regimen outside a clinical study, will have had cirrhosis confirmed prior to initiation of hcv treatment. key exclusion criteria: * individuals planning to initiate a new course of hcv therapy, including approved products and any investigational agents, during the course of this registry * history of clinically-significant illness or any other major medical disorder that may interfere with the follow-up, assessments, or compliance with the protocol note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: hcv cirrhosis registry cirrhosis hepatitis c
surveillance pelvic examination anxiety: brief coping skills intervention

Conditions: Anxiety

Summary: the purpose of this study is to test the feasibility and acceptability of a brief coping skills training program addressing anxiety and pain related to surveillance pelvic examinations for female gynecologic cancer survivors.

the investigators have developed and manualized a coping skills training intervention for female gynecologic cancer patients that aims to reduce anxiety related to surveillance pelvic examinations (pelvic examination and anxiety coping skills for empowerment: peace). the investigators propose a proof-of concept pilot study to evaluate the acceptability and feasibility of the coping skills intervention. the study will be conducted by duke university. participants (n=16) will receive the 3-session telemedicine coping skills intervention. participants will complete assessments at baseline, post-intervention (within 2 weeks before their next scheduled pelvic examination), and post pelvic examination (2-3 months after the baseline assessment). study aims are: aim 1) assess intervention acceptability and feasibility through quantitative measurement and qualitative feedback from semi-structured interviews, and aim 2) graphically depict patterns of change in outcome variables and intervention targets.

Eligibility criteria:
inclusion criteria: * female sex * diagnosis of stage i-iv cervical or endometrial cancer * 18 years of age or older * able to speak/read english * able to give informed consent * completed cancer treatments within 2-24 months prior to enrollment, and recommended to undergo surveillance pelvic examination at three month intervals * able to commit to three 45-60 minute visits within the study period * able to participate in the intervention via the telemedicine modality (e.g., phone or video) exclusion criteria: * unable to provide informed consent * major untreated or uncontrolled mental illness * hearing impairment that impedes telephone or video calls
outreach to reduce depression disparities

Conditions: Depression

Summary: previous research by mental health research network (mhrn) investigators and others demonstrates that online messaging and other telehealth technologies can effectively and efficiently address premature discontinuation of depression treatment. these interventions, however, have focused on adherence after treatment initiation and have been tested primarily in non-hispanic white populations. less is known about the acceptability and effectiveness of different communication modalities (online messaging, mailed letters, telephone) among racial and ethnic minority populations. implementation of electronic-health (ehealth) technologies must take care not to exacerbate health disparities. this clinical trial involves a pilot trial to evaluate a population-based outreach program to improve rates of depression treatment initiation among traditionally underserved racial and ethnic groups. this pilot work intends to inform a subsequent full-scale pragmatic trial to examine impact on health disparities.


Eligibility criteria:
inclusion criteria: * new diagnosis of major depressive disorder or dysthymic disorder at a primary care visit ("new" defined as no depression diagnosis, psychotherapy visit or filled antidepressant prescription in the prior year) * continuously enrolled in the participating health system for 365 days prior to the eligible diagnosis (to assure capture of prior diagnoses or treatments) * patients health questionnaire-9 (phq-9) depression score of 10 or more within 14 days before to 7 days after the eligible diagnosis * no filled prescription for any antidepressant medication or psychotherapy visit attended within 30 days of the eligible diagnosis\* * no recorded phq-9 depression score less than 5 since the eligible diagnosis * at least 18 years of age or older exclusion criteria: * diagnosis of schizophrenia or bipolar disorder in the prior 2 years * not registered to use electronic health record (ehr) patient portal * previously requested to not be contacted for research
multiprofen-cc to reduce pain in hand arthritis

Conditions: Hand Osteoarthritis

Summary: this clinical trial aims to find out if using 1 gram of multiprofen-cc cream on the hands three times a day for 4 weeks can help reduce pain in adults with hand osteoarthritis, compared to a placebo (a cream with no active medicine). the research team will also look at how multiprofen-cc affects hand function, opioid use, and how patients feel about their overall improvement. in addition, the research team will keep track of any side effects. participants will: * use both multiprofen-cc and a placebo (a cream with no active medicine) during the study, in a random order. * be asked to apply 1 gram of cream to their hands three times a day for 2 weeks, following the manufacturer's instructions. * attend a visit before starting the study, after 2 weeks, and after 6 weeks. * report any symptoms they experience during the study.


Eligibility criteria:
inclusion criteria: * adults (18+) * have been diagnosed with hand osteoarthritis according to american college of rheumatology criteria * experience pain and/or loss of function in one or both hands that interferes with daily life * provide informed consent exclusion criteria: * unable to consent * unable or unwilling to follow study protocol * known allergy or contraindication to any of the study drugs or their ingredients * have open wounds/cuts and/or skin conditions on the hand area * pregnant or breastfeeding * history of impaired kidney or liver function * rheumatoid or other inflammatory arthropathy * hand surgery within the past 6 months or planned within the study period. * use daily opioids (other than short acting codeine) for a chronic pain condition other than hand arthritis

Keywords: hand osteoarthritis osteoarthritis arthritis topical multiprofen
adaptive radiotherapy and mris based on patients with newly diagnosed high-grade glioma

Conditions: Glioblastoma; Anaplastic Astrocytoma; Astrocytoma; Anaplastic Oligodendroglioma

Summary: the purpose of this study is to find out if performing additional magnetic resonance image (mri) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.

diffusion weighted imaging (dwi) and perfusion-weighted imaging (pwi) are validated mri techniques that aid in diagnosis, prognosis, and assessment of treatment efficacy and, while they are utilized in select clinical settings, they have yet to make their way into routine clinical practice at most centers. dwi is a non-invasive mri modality that has demonstrated an ability to predict for a response to radiation therapy in the primary treatment of patients with glioblastoma (gbm). pwi is one collection of measures that includes dynamic susceptibility contrast (dsc) enhancement and dynamic contrast-enhanced (dce) imaging. the latter methods of mri-adapted radiotherapy allow the opportunity to direct high-dose radiation to areas most likely to harbor resistant tumor while avoiding regions having a low likelihood of future recurrence. multiple mri sequences have been developed and validated that may identify high-risk areas in patients with high-grade glioma (hgg) and the ability to acquire multiple sequential time points creates an opportunity for dynamic radiotherapy that has not previously been explored. the current standard of care in radiotherapy does not incorporate any additional neuroimaging data. this study hypothesizes that pre- and mid-treatment advanced imaging with (dwi) and (pwi) in patients with hgg can be used to generate an adaptive radiotherapy boost volume that correlates with areas of future recurrence and that this volume has a higher spatial correlation relative to the current standard of care.

Eligibility criteria:
inclusion criteria: * histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma * history and physical examination within 28 days prior to enrollment * karnofsky performance status 70 or greater * age 18 years or greater * negative pregnancy test for females of childbearing potential before 1st research mri, performed in accordance to institutional guidelines. * plan to receive 59.4-60 gy in 30-33 fractions of radiotherapy. glioblastoma patients over 65 year-old can receive hypofractionated radiotherapy including 40 gy in 15 fractions. exclusion criteria: * prior therapy for tumor except for biopsy or resection, including prior radiotherapy to the brain. * clinical or radiological evidence of metastatic disease outside the brain * prior malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years

Keywords: adaptive radiotherapy high-grade glioma perfusion-weighted imaging diffusion weighted imaging
different genetic features associated with hepatic carcinogenesis

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to identify different genetic features in hepatocellular carcinoma. it will assist in predicting individual risks of disease progression and would help to clarify pathophysiological mechanisms of hcc.

hepatocellular carcinoma (hcc) is a leading cause of cancer deaths in taiwan. hcc normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. surgical resection and liver transplantation are current best curative options to treat hcc. however, recurrence or metastasis is quite common in patients who have had a resection and survival rate is 30% to 40% at 5 years postoperatively. micrornas, small non-coding rna, act as endogenous rna interference by post-transcription regulation. recent studies suggest that micrornas may act as tumor suppressors or oncogenes and altered microrna expression levels may play an important role in the cancer initiation and progression. several studies, including ourselves, have shown that specific micrornas are aberrantly expressed in malignant hcc tissues compared to normal counterpart. although many microrna profiling studies were done to diagnose hepatocarcinogenesis, data about prognostic significances for postsurgical survival are very limited. the main point of this study is to develop a predictive signature for postsurgical survival in hcc patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hepatocellular carcinoma exclusion criteria: -

Keywords: microrna
digital therapeutic for depression after head injury in current and former us military personnel

Conditions: Depressive Symptoms; Mild Traumatic Brain Injury

Summary: the center for neuroscience and regenerative medicine (cnrm) clinical trials unit has developed the first cognitive-behavioral therapy (cbt) digital therapeutic (dtx) mobile application to counteract depressive symptoms in military service members and veterans with a history of mild traumatic brain injury (mtbi). this trial will assess the efficacy of the novel cbt-dtx for depression following mtbi compared to an educational comparison dtx.

this trial is a single-blind, randomized, controlled interventional trial of current and former military personnel with symptoms of depression and a history of mtbi. the study will be conducted remotely.

Eligibility criteria:
inclusion criteria: * be aged ≥ 18 to ≤ 65 years * be able to provide informed consent * diagnosed with mild tbi as defined by the department of veteran's affairs and department of defense clinical practice * have a phq-9 score of ≥ 5 to 27, indicative of mild or greater depressive symptoms * have ownership of or reliable access to a smartphone with a data plan or internet connecting capabilities * while participating in this study, be able to ensure that you have access to regular care for mental health and to speak with your provider as necessary exclusion criteria: * report of starting pharmacological or non-pharmacological treatment for depression within the 3 months prior to trial enrollment * report a recent change in type or dose of antidepressant medications within 12 weeks prior to trial enrollment * report active psychotic or bipolar symptoms * active plan and/or intent of suicide or homicide * in the opinion of the investigator, they have other considerations that may adversely affect patient safety, participation, or scientific validity of the data being collected
coagulation profile in patients undergoing video assisted thorascopic surgery (vats) for lung cancer

Conditions: Lung Cancer

Summary: the purpose of the study is: to estimate patients with lung cancers who will undergo surgery total haemostatic / thrombotic capacity pre, per-and postoperatively. to investigate whether prophylactic treatment with low molecular weight heparin (lmwh) affects the patient's potential hypercoagulability. to investigate whether there are differences in patients who will undergo video assisted thorascopic surgery (vats) or open surgery in regards of impact of the coagulation system.

lung cancer is a serious and very frequent disease. for those 25% of the patients who will undergo surgery, there are two different methods of operation: either open surgery (thoracotomy) or video assisted thorascopic surgery (vats). the latter method is increasing in use. patients are often prescribed heparin pre- postoperatively, but it is unclear whether this prophylactic treatment is necessary, and it has never been thoroughly investigated. when patients receive heparin there is an increased risk of bleeding. furthermore, it is unclear what changes occurs in the coagulation system pre, per- and postoperatively in patients undergoing surgery for lung-cancer, and hereby it is unclear whether these patients should have some sort of medical prophylactic treatment. by using new analysis methods in terms of thromboelastometry, thrombin generation and thrombocyte function analysis, hereby the total coagulation profile can be characterized and hereby estimate the risk of thrombosis and bleeding. thereby better be able to give the right treatment for these patients.

Eligibility criteria:
inclusion criteria: * undergo surgery for lung cancer with an expected lobectomy or bilobectomy * the surgery shall be vats (for patients in the group randomized to other low molecular weight heparin and no prophylactic) * willing to be randomized (vats-patients) * over 18 years old. * able to give assigned informed consent * women should be prescribed secure anticonception. exclusion criteria: * thromboembolic events within the last three months (both venous and arterial) * pregnant * lactating * treatment with anticoagulation therapy in terms of vitamin k antagonist or direct or indirect thrombin inhibitors (dabigatran, apixaban or rivaroxaban) * treatment with thrombocyte function inhibitors in terms of clopidogrel, asa (acetylsalicylic acid), prasugrel and ticagrelor, and no pause of minimum 5 days (7 days with regards of prasugrel) before surgery * allergy for lmwh

Keywords: lung cancer surgery thromboembolism bleeding
effect of taping in the hemiplegic patient with a deficit of the footbrowers

Conditions: Hemiplegia

Summary: a majority of people undergoing rehabilitation following a stroke have a deficit of the dorsal flexors of the foot. the implementation of rehabilitation techniques in accordance with the recommendations of learned societies is not sufficient to compensate for this deficit. also kinesio taping's method of dr. kenzo kase has caught our attention by its action on muscle, joint, circulatory and pain functions. the use of taping would increase the duration of stimulation of the muscles of the dorsiflexors of the foot which would facilitate the motor recovery. data from the literature do not support the conclusion that taping is effective, but no studies evaluating the efficacy of this technique in the foot-lift deficiency of the hemiplegic patient have been found. the investigators hypothesize that the use of taping in conjunction with common rehabilitation for hemiplegic patients following a stroke improves the stimulation of the muscles of the dorsiflexors of the foot with a positive impact on the walking.


Eligibility criteria:
inclusion criteria: * patient with a stroke occurring in a period ranging from 15 days to a month before inclusion and presenting left or right hemiplegia. * voluntary motricity of the dorsal flexors of the foot greater than or equal to 1 on the scale of held and pierrot deseilligny * quadriceps voluntary motor skill greater than or equal to 2 on the scale of held and pierrot deseilligny * informed consent of the patient. exclusion criteria: * - evolutive neurological disease leading to cognitive impairment (alzheimer's, parkinson's, multiple sclerosis ...) * pre-stroke neurological sequelae * achilles tendon elongation or tendinous transfer surgery. * spasticity of the sural triceps greater than 2 on the modified ashworth scale * injection of botulinum toxin * patients under guardianship, curatorships or under safeguard of justice. * allergy to glue, skin lesions located on the zone of laying of the bands * complex regional pain symptom of the ankle
phenobarbital versus valproate for generalized convulsive status epilepticus

Conditions: Generalized Convulsive Status Epilepticus

Summary: although generalized convulsive status epilepticus (gcse) is a life-threatening emergency, evidence-based data to guide initial drug treatment choices are lacking in the chinese population. the investigators conduct this prospective randomized controlled trial to evaluate the relative efficacy and safety of intravenous (iv) phenobarbital (pb) and valproate (vpa) in patients with gcse.

after the failure of first-line diazepam treatment, patients with gcse are randomized to receive either iv pb (standard doses, low rate) or vpa (standard). successful treatment is considered when clinical and electroencephalographic seizure activity ceases. adverse events following treatment and the neurological outcomes at discharge and 3 months later are also evaluated.

Eligibility criteria:
inclusion criteria: * all consecutive gcse patients (after the failure of first-line diazepam treatment) who were admitted in the emergency room or neurocritical care unit in xuanwu hospital of capital medical university. exclusion criteria: * unstable vital signs, such as a systolic blood pressure of \<90 mm hg, a pulse of \<60 beats per min, or an arterial blood oxygen saturation of \<90%, * liver dysfunction (alanine transaminase or total bilirubin of more than twice the normal upper limit), * neurologic emergency requiring immediate surgical intervention, * pregnancy or breast feeding, * hypersensitivity to study drugs.
the use of ethinylestradiol/dienogest in random start rapid endometrial preparation

Conditions: Endometrial Polyp; Endometrial Diseases

Summary: the presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. we explored the efficacy of random started 14-day administration of ethinylestradiol/dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy.


Eligibility criteria:
inclusion criteria: * patients with endometrial polyps. exclusion criteria: * patients with other endometrial pathologies.

Keywords: hysteroscopy endometrial preparation
comparing immunogenicity and safety of different formulations of hbv-mpl vaccine with engerix™-b in adults aged 19-40 y

Conditions: Hepatitis B

Summary: this study will evaluate the immunogenicity and safety of different formulations of the hbv-mpl vaccine administered according to a 2-dose schedule and compare it to that of engerix™-b administered according to a 3-dose schedule in order to determine the optimal dose of each component of the candidate hbv-mpl vaccine when administered at 0 and 6 months

at the time of conduct of this study, the sponsor glaxosmithkline was known by its former name smithkline beecham

Eligibility criteria:
inclusion criteria: * age: between 19 and 40 years old. * good physical condition as established by clinical examination and history taking at the time of entry. * female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. * written informed consent obtained from the subjects exclusion criteria: * positive titres at screening for anti-hepatitis antibodies. * elevated serum liver enzymes. * history of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease. * any acute disease at the moment of entry. * chronic alcohol consumption. * hepatomegaly, right upper quadrant abdominal pain or tenderness. * any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study. * history of allergic disease likely to be stimulated by any component of the vaccine. * simultaneous participation in any other clinical trial. * previous vaccination with a hepatitis b vaccine. * previous vaccination with an mpl containing vaccine. * administration of immunoglobulins in the past 3 months and during the whole study period * vaccination one month before and one month after each dose of the study vaccine

Keywords: hepatitis b hbv-mpl recombinant hepatitis b vaccine